EcoDrugPlus

Cholecystokinin A Receptor

Ensembl ID : ENSPSNG00000021657
Gene Symbol: CCKAR
3 Cross references
200 Possible Orthologues:

Cholecystokinin B Receptor

Ensembl ID : ENSPSNG00000009408
Gene Symbol: CCKBR
3 Cross references
264 Possible Orthologues:

Cholinergic Receptor Muscarinic 1

Ensembl ID : ENSPSNG00000019868
Gene Symbol: CHRM1
3 Cross references
101 Possible Orthologues:

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSPSNG00000020802
Gene Symbol: CHRM2
3 Cross references
259 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSPSNG00000019748
Gene Symbol: CHRM3
3 Cross references
255 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSPSNG00000005202
Gene Symbol: CHRM4
1 Cross references
184 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSPSNG00000009687
Gene Symbol: CHRM5
3 Cross references
263 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSPSNG00000000884
Gene Symbol: CHRNA3
3 Cross references
207 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSPSNG00000020351
Gene Symbol: CHRNA4
3 Cross references
204 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 7 Subunit

Ensembl ID : ENSPSNG00000008735
Gene Symbol: CHRNA7
3 Cross references
243 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSPSNG00000003203
Gene Symbol: CHRNB2
3 Cross references
197 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSPSNG00000000903
Gene Symbol: CHRNB4
1 Cross references
198 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).